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AZA

:   azathioprine

CyA

:   cyclosporine

ESRD

:   end‐stage renal disease

FK

:   tacrolimus

GAD65

:   65‐kDa glutamic acid decarboxylase isoform

GADA

:   GAD65 autoantibody

HG

:   hyperglycemia

HG‐T1DR

:   hyperglycemia with T1D recurrence

HG‐PCR

:   hyperglycemia with pancreas chronic rejection

HG‐UND

:   hyperglycemia of undetermined cause

HR

:   hazard ratio

IA‐2

:   insulinoma‐associated tyrosine phosphatase‐like protein

IA‐2A

:   IA‐2 autoantibody

MMF

:   mycophenolate mofetil

NGT

:   normal glucose tolerance

OKT3

:   anti‐CD3, muromonab

PPV

:   positive predictive value

SEM

:   standard error of the mean

SPK

:   simultaneous pancreas--kidney

T1D

:   type 1 diabetes

ZnT8

:   zinc transporter 8

ZnT8A

:   ZnT8 autoantibody

Introduction {#ajt13426-sec-0002}
============

Islet autoimmunity causes progressive loss of pancreatic beta cells, leading to impaired insulin secretion and the development of type 1 diabetes (T1D) [1](#ajt13426-bib-0001){ref-type="ref"}. Several islet autoantigens are targeted by both cellular and humoral responses. Standardized assays measure autoantibodies to insulin, the 65‐kDa glutamic acid decarboxylase isoform (GAD65), the insulinoma‐associated tyrosine phosphatase‐like protein (IA‐2), and zinc transporter 8 (ZnT8). Autoantibodies are robust diagnostic and predictive T1D markers, with multiple autoantibodies conferring much higher risk than single autoantibody positivity [2](#ajt13426-bib-0002){ref-type="ref"}, [3](#ajt13426-bib-0003){ref-type="ref"}, [4](#ajt13426-bib-0004){ref-type="ref"}, [5](#ajt13426-bib-0005){ref-type="ref"}, [6](#ajt13426-bib-0006){ref-type="ref"}, [7](#ajt13426-bib-0007){ref-type="ref"}.

Simultaneous pancreas--kidney (SPK) transplantation restores insulin secretion and renal function in T1D patients with end‐stage renal disease (ESRD) [8](#ajt13426-bib-0008){ref-type="ref"}. However, recipients may develop posttransplant diabetes, a broad clinical entity with multifactorial etiology including effects of immunosuppression, insulin resistance, weight gain, and others [9](#ajt13426-bib-0009){ref-type="ref"}, [10](#ajt13426-bib-0010){ref-type="ref"}. With advances in immunosuppression, acute rejection has become less prevalent and immunological failures are typically ascribed to chronic rejection [8](#ajt13426-bib-0008){ref-type="ref"}. However, another potential cause of immunological failure is T1D recurrence [11](#ajt13426-bib-0011){ref-type="ref"}, [12](#ajt13426-bib-0012){ref-type="ref"}. A growing literature suggests that islet autoimmunity may become reactivated and affect the endocrine function of pancreas transplants [11](#ajt13426-bib-0011){ref-type="ref"}, [13](#ajt13426-bib-0013){ref-type="ref"}, [14](#ajt13426-bib-0014){ref-type="ref"}, [15](#ajt13426-bib-0015){ref-type="ref"}, [16](#ajt13426-bib-0016){ref-type="ref"}, [17](#ajt13426-bib-0017){ref-type="ref"}, [18](#ajt13426-bib-0018){ref-type="ref"}, [19](#ajt13426-bib-0019){ref-type="ref"}, [20](#ajt13426-bib-0020){ref-type="ref"}, [21](#ajt13426-bib-0021){ref-type="ref"}, [22](#ajt13426-bib-0022){ref-type="ref"}, [23](#ajt13426-bib-0023){ref-type="ref"}, [24](#ajt13426-bib-0024){ref-type="ref"}, [25](#ajt13426-bib-0025){ref-type="ref"}, [26](#ajt13426-bib-0026){ref-type="ref"}, [27](#ajt13426-bib-0027){ref-type="ref"}, [28](#ajt13426-bib-0028){ref-type="ref"}, [29](#ajt13426-bib-0029){ref-type="ref"}.

In this longitudinal study, we assessed T1D recurrence in a large cohort of 223 SPK recipients. We find that even with the current immunosuppression regimen, T1D recurrence is a common cause of posttransplant diabetes, no less frequent than diabetes resulting from pancreas chronic rejection. Further, we define immunological, genetic, and therapeutic risk factors for T1D recurrence. We show that monitoring islet autoimmunity and assessment of other risk factors help predict and correctly diagnose T1D recurrence.

Subjects and Methods {#ajt13426-sec-0003}
====================

Subjects {#ajt13426-sec-0004}
--------

We studied T1D patients with ESRD who received SPK transplants. All had no detectable c‐peptide response to a Sustacal/Boost test (Société des Produits Nestlé S.A., Vevey, Switzerland) before transplantation. All pancreas transplants were bladder‐drained with systemic venous effluent. We monitored urine amylase levels to aid in assessing pancreatic exocrine graft function and rejection; patients generally exhibit a stable range of amylase levels in units/hour (h) during a 12‐h overnight collection. A reduction in levels is suggestive of rejection. Between 1990 and 2013, 452 T1D patients underwent SPK transplantation at the University of Miami. The Institutional Review Board approved this study (\#20053039) to evaluate islet autoimmunity. Participation was voluntary; subjects could withdraw at any time without affecting access to standard care. For some patients, outcome data and archived serum samples were evaluated under waiver of consent.

Patient classification according to pancreas graft outcomes {#ajt13426-sec-0005}
-----------------------------------------------------------

This analysis included 223 SPK recipients who had at least one year of post‐transplant follow‐up and for whom we could define overall autoantibody status prior to and after transplantation for the duration of the follow‐up. The 223 patients were transplanted between 1990 and 2012, with the last follow‐up sample collected in 2013. The demographic characteristics are shown in Table [1](#ajt13426-tbl-0001){ref-type="table-wrap"}. The mean follow‐up was 6.2 ± standard deviation (SD) 4.1 years, range 1.0--22.6 years. Follow‐up started with the transplant and ended with the development of hyperglycemia or with the last sample obtained by December 2013 for those who were still normoglycemic. Patients were classified as normal glucose tolerant (NGT) if their HbA1c was ≤6.1% (the normal range in our laboratory is 4.5--6.1%) in the absence of insulin therapy or antidiabetic oral medications. Patients were categorized as having hyperglycemia (HG) if, on further follow‐up after posttransplant normalization of glucose metabolism, their HbA1c levels returned to the abnormal range and/or if they required antidiabetic therapy (oral agents, insulin, or both). We classified the HG group into three subgroups based on clinical features: HG with T1D recurrence (HG‐T1DR): presence of classical diabetes symptoms with hyperglycemia requiring insulin therapy, severe loss of C‐peptide in the absence of rejection (stable urine amylase and serum creatinine levels);HG with pancreas chronic rejection (HG‐PCR): hyperglycemia associated with loss of urine amylase; biopsy‐proven rejection in some instances;HG with undetermined cause (HG‐UND): mild diabetes symptoms, typically not requiring insulin therapy, persisting C‐peptide secretion, often associated with obesity or significant weight gain; lack of clear signs of rejection.

###### 

Demographic and clinical features, overall and by analysis groups

                                                      All patients   NGT          HG‐T1DR       HG‐PCR       HG‐UND       p value
  --------------------------------------------------- -------------- ------------ ------------- ------------ ------------ -------------------------------------------------
  N                                                   223            176          17            10           20           n/a
  \% of total (223)                                   n/a            78.9         7.6           4.5          9            n/a
  \% of HG (47)                                       n/a            n/a          36.2          21.3         42.6         n/a
  Sex (F‐M)                                           106--117       89--87       8--9          1--9         8--12        p=0.1494^1^
  White not Hispanic, n (%)                           117 (52.5)     96 (54.5)    9 (52.9)      5 (50.0)     7 (35.0)     p=0.3028^2^
  White Hispanic, n (%)                               83 (37.2)      63 (35.8)    8 (47.1)      3 (30.0)     9 (45.0)     n/a
  African‐American, n (%)                             22 (9.9)       16 (9.1)     0             2 (20.0)     4 (20.0)     n/a
  Other, n (%)                                        1 (0.4)        1 (0.6)      0             0            0            n/a
  Age at T1D onset mean ± SD (years)                  14 ± 8.6       14.3 ± 8.4   13.9 ± 10.7   9.1 ± 5.3    14.7 ± 8.8   p=0.3159[a](#ajt13426-note-0003){ref-type="fn"}
  Range (years)                                       0--39          0--38        2--39         1--17        4--32        n/a
  Patients with no available data                     2              1            0             0            1            n/a
  T1D duration at transplantation mean ± SD (years)   26.6 ± 8.6     27.5 ± 8.4   20.9 ± 10.0   27.6 ± 5.0   23.1 ± 7.8   **p = 0.0161**
  Range (years)                                       2--50          3--50        2--39         22--35       8--36        n/a
  Patients with no available data                     2              1            0             0            1            n/a
  Age at transplant mean ± SD (years)                 40.7 ± 8.0     41.8 ± 8.1   34.8 ± 6.6    36.6 ± 4.4   38.2 ± 6.3   **p = 0.0006**
  Range (years)                                       23--60         23--60       23--47        30--44       29--50       n/a
  Length of follow‐up mean ± SD (years)               6.2 ± 4.1      6.2 ± 4.2    6.8 ± 3.8     4.5 ± 2.9    6.2 ± 4.4    p = 0.5029\*
  Range (years)                                       1.0--22.6      1.0--22.6    2.2--17.2     2.1--10.3    1.1--15.6    n/a
  Last HbA1c on follow‐up mean ± SD                   5.7 ± 0.7      5.5 ± 0.4    6.9 ± 0.9     6.9 ± 1.1    7.1 ± 0.8    **p \< 0.0001**
  Patients with no available data                     54             32           12            7            3            n/a

HG‐PCR, hyperglycemia with pancreas chronic rejection; HG‐T1DR, hyperglycemia with type 1 diabetes recurrence; NGT, normal glucose tolerance.

Overall p values of the chi‐square test are shown for independence between sex^1^ or ethnicity^2^ (excluding "other") and group classification (NGT, HG‐T1DR, HG‐PCR, HG‐UND).

One‐ way analysis of variance (Global Kruskal--Wallis test).
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Autoantibody testing of longitudinal samples {#ajt13426-sec-0006}
--------------------------------------------

For each patient, we tested a pretransplant and multiple follow‐up serum samples. Patients had a mean 4.8 ± SD 3.1 samples tested per year of follow‐up (range 0.6--17.1 per year, only 5 patients had less than one sample/year tested on average). We used well‐established radioimmunoassays (RIA) to measure autoantibodies to the autoantigens GAD65 (GADA), IA‐2 (IA‐2A), and ZnT8 (ZnT8A) (Supplementary Methods). We did not measure insulin autoantibodies since antibodies to insulin are induced by insulin therapy in most patients, and these cannot be distinguished from autoantibodies.

Genetic typing {#ajt13426-sec-0007}
--------------

Donors and recipients were HLA typed, by standard serology and/or molecular techniques, at the time of transplantation. A subset of 19 donor--recipient pairs, from whom DNA was available from a pancreas transplant biopsy (donor) and blood (recipient), were typed at SCL30A8 locus, as described in Supplementary Methods.

Statistical analysis {#ajt13426-sec-0008}
--------------------

Nonparametric comparisons of group differences, such as Mann--Whitney test and Kruskal--Wallis test (one‐way analysis of variance) were used for quantitative variables, applying Dunn\'s correction for multiple comparisons where appropriate. Categorical variables between groups were compared with the chi‐square and Fisher\'s exact tests. Kaplan--Meier curves were used to estimate hyperglycemia‐free survival; significant differences in survival distributions were assessed with the log‐rank test, unless otherwise noted, after verification of proportional hazard assumptions, with Bonferroni corrections applied for multiple comparisons. Two‐tailed tests of significance and a Type I error rate of 0.05 are used throughout. Statistical analysis was performed with either SAS 9.3 (SAS, Cary, NC) or GraphPad Prism 6.0 (Graphpad Software, La Jolla, CA).

Results {#ajt13426-sec-0009}
=======

Development of posttransplant diabetes {#ajt13426-sec-0010}
--------------------------------------

Most patients (n = 176, 78.9%) were normoglycemic at the end of the follow‐up (mean follow‐up length=6.2 ± SD 4.2 years, range 1--22.6 years, Table [1](#ajt13426-tbl-0001){ref-type="table-wrap"}). Forty‐seven patients (21.1%) developed posttransplant diabetes (HG group); 17 patients (7.6% overall, 36.2% of the HG group) had a clinical diagnosis of HG‐T1DR; this was confirmed by examination of a pancreas transplant biopsy in 15/17 (88%) patients, which demonstrated the presence of insulitis in 13/15 (87%) patients and significant loss of insulin staining in all (Table S1A) [11](#ajt13426-bib-0011){ref-type="ref"}; thus, biopsy‐confirmed HG‐T1DR was found in 5.8% of our recipients (13/223). Although several of the patients had some biopsy evidence of coexisting pancreas rejection (Table S1B), this ranged from minimal to moderate in most with severe chronic rejection observed in a single patient (patient 5). Only 5 patients had coexisting laboratory findings suggestive of pancreas rejection given urine amylase levels \<1000 units/h (patients 2, 6, 8, 9, and 11, Table S1B).

Ten patients (4.5% overall, 21.3% of the HG group) developed hyperglycemia with a clinical diagnosis of HG‐PCR. Twenty patients (9.0% overall and 42.6% of the HG group) developed hyperglycemia of undetermined cause (HG‐UND). The duration of follow‐up was comparable among NGT and HG groups (Table [1](#ajt13426-tbl-0001){ref-type="table-wrap"}). The HG‐T1DR group had shorter T1D duration at transplantation compared to the NGT group (difference = 6.6 years, p = 0.0237). The patients who developed HG‐T1DR were significantly younger at transplantation than those in the NGT group (p = 0.0021). All HG groups had significantly higher HbA1c levels compared to NGT (HG‐T1DR, p = 0.0006; HG‐PCR, p = 0.0135; HG‐UND, p \< 0.0001).

Influence of immunosuppression on the development of T1D recurrence {#ajt13426-sec-0011}
-------------------------------------------------------------------

We investigated whether immunosuppression, which has evolved over time, influences the development of T1D recurrence (Table [2](#ajt13426-tbl-0002){ref-type="table-wrap"}). Using Kaplan--Meier estimates of survival, we evaluated hazard ratios with log‐rank tests of significance.T1D recurrence was more common in patients who did not receive induction therapy (Group B, Figure [1](#ajt13426-fig-0001){ref-type="fig"}, hazard ratio \[HR\] = 6.324, p = 0.0036) compared to Group D where induction was achieved with thymoglobulin and anti‐CD25; these groups received the same maintenance therapy. Group B also had a higher incidence of T1D recurrence compared to Groups D + E, which included patients treated with the current regimen (since year 2000, induction with thymoglobulin and anti‐CD25 and maintenance with steroids, tacrolimus \[FK\], and either rapamycin or mycophenolate mofetil \[MMF\]; Figure [1](#ajt13426-fig-0001){ref-type="fig"}, HR = 6.058, p = 0.0011). There was no effect associated with rapamycin or MMF. Induction with anti‐CD3, muromonab (OKT3) (Group A) resulted in comparable survival with the current regimen and lower T1D recurrence risk compared to the no‐induction regimen (Group B, p = 0.0530).

###### 

Patient groups according to immunosuppression regimens

  Group   Period                                      Patients (n)                Induction therapy             Maintenance therapy                                                 Years of follow‐up (mean ± SEM) (range)   HG‐T1DR   Years from Tx to HG‐T1DR (mean ± SEM) (range)
  ------- ------------------------------------------- --------------------------- ----------------------------- ------------------------------------------------------------------- ----------------------------------------- --------- ------------------------------------------------------------------
  A       6/13/1990--5/6/1997                         16                          OKT3 (n = 16)                 CyA (n = 4) or FK (n = 12), AZA (n = 14) or MMF (n = 2), steroids   9.12 ± 1.20 (2.78--19.07)                 4         10.79 ± 2.16 (8.18--17.18)
  B       8/2/1997--6/14/2000                         19                          No induction (n = 11)         FK, MMF, steroids (n = 19)                                          7.12 ± 1.11 (4.81--7.93)                  5         5.81 ± 0.58[a](#ajt13426-note-0005){ref-type="fn"} (2.78--19.07)
  C       Anti‐CD25 (n = 8)                           7.21 ± 1.77 (2.25--14.07)   1                             2.25 (na)                                                                                                               
  D       9/6/2000--9/30/2013                         108                         Thymo + Anti‐CD25 (n = 108)   FK, MMF, steroids (n=55)                                            5.51 ± 0.47 (0.94--11.52)                 3         7.07 ± 1.52 (4.09--9.08)
  E       FK, rapamycin, steroids (n=53)              4.22 ± 0.38 (0.99--10.66)   2                             2.38 ± 1.10 (1.28--3.48)                                                                                                
  D+E     FK, MMF, or rapamycin, steroids (n = 108)   4.88 ± 0.31 (0.94--11.52)   5                             5.19 ± 1.46 (1.28--9.08)                                                                                                
          Total                                       143                                                                                                                           15                                                  

Immunosuppression regimens used at our center, inclusive dates, number of patients in each group, and development of HG‐T1DR. This analysis does not include 80 patients who developed hyperglycemia following rejection or for undetermined cause, and/or who had significant changes in maintenance immunosuppression on follow‐up and would be difficult to assign to a treatment group; the single patient treated with Minnesota anti‐lymphocyte globulin (MALG) was not included. Data are shown for 143 patients: 119 had no changes to maintenance therapy on follow‐up, 24 patients had only early changes (within 6 months) in maintenance drugs and afterwards remained on the same regimens; 128 patients had normal glucose tolerance by the end of follow‐up and 15 patients had developed HG‐T1DR.

Time from transplantation to diagnosis of HG‐T1DR was significantly shorter for Group B when compared to Group A, p = 0.0159; no other comparisons showed statistical differences.

HG‐T1DR, hyperglycemia with type 1 diabetes recurrence; OKT3, anti‐CD3, muromonab; anti‐CD25, daclizumab or basiliximab; CyA, cyclosporine; FK, tacrolimus; AZA, azathiprine; MMF, mycofenilate mofetil.
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![**Effects of immunosuppression on type 1 diabetes recurrence.** Kaplan--Meier analysis of HG‐T1DR‐free survival according to the immunosuppression regimens used. Regimens used in each of the groups are shown in Table [2](#ajt13426-tbl-0002){ref-type="table-wrap"}. Group B had a higher incidence of HG‐T1DR compared to Group D (HR = 6.324, p = 0.0036\*) and Group D+E (HR = 6.058, p = 0.0011\*). Group B and Group C did not differ (HR = 2.674, p = 0.3458), similar to Group A vs. Group B (HR = 3.23, p = 0.0530), Group C (HR = 1.106, p = 0.9292), and Group D+E (HR = 1.49, p = 0.4856). There was no difference in the incidence of HG‐T1DR between Group D and Group E (HR = 1.178, p = 0.8538). \*Significant after correction for multiple comparisons. HG‐T1DR, hyperglycemia with type 1 diabetes recurrence.](AJT-16-235-g001){#ajt13426-fig-0001}

Autoantibody status and patterns defined by pre‐ and posttransplant analysis {#ajt13426-sec-0012}
----------------------------------------------------------------------------

We assessed T1D‐associated autoantibodies in our cohort to investigate whether autoantibodies are associated with T1D recurrence. Patients were classified as autoantibody‐negative (Figure [2](#ajt13426-fig-0002){ref-type="fig"}) if they had no autoantibodies pretransplant and on follow‐up (n = 97); this group included a small number of patients (n = 28/223, 12.5%) with sporadic autoantibody positivity, at very low levels and inconsistent for autoantibody type, who similar to the autoantibody‐negative group showed no association with hyperglycemia (not shown). Patients who were positive pretransplant but converted to negative soon after transplantation (n = 19) were also considered autoantibody‐negative overall. On posttransplant follow‐up (Table S2, Figure [2](#ajt13426-fig-0002){ref-type="fig"}), the proportions of autoantibody‐negative and autoantibody‐positive patients changed little (pre‐ to posttransplant, 57--52% negative, 43--48% positive). However, the determination of pre‐ and posttransplant autoantibody status allowed us to appreciate changes and thus define two patterns of autoantibody positivity, persistence, and conversion. Patients who were autoantibody‐positive pretransplant and remained positive without acquiring additional autoantibodies were classified as having autoantibody persistence (n = 57, 25.6%). Patients who were autoantibody‐negative pretransplant and became autoantibody‐positive on follow‐up, or if positive pretransplant later acquired additional autoantibodies, were defined as having an autoantibody conversion pattern (n = 50, 22.4%).

![**Autoantibody patterns.** Autoantibody status pre‐ and posttransplant, based on which we determined overall autoantibody patterns (negative, conversion, persistence) in 223 SPK recipients.\*Eight patients could not be tested for ZnT8A pretransplant but were always negative on follow‐up and were assumed to be negative for this analysis of overall autoantibody status. SPK, simultaneous pancreas--kidney.](AJT-16-235-g002){#ajt13426-fig-0002}

Pretransplant autoantibody status does not predict future pancreas graft endocrine function {#ajt13426-sec-0013}
-------------------------------------------------------------------------------------------

Pretransplant, 43% of the patients had at least one T1D‐associated autoantibody, despite having developed T1D on average two decades earlier (Tables [1](#ajt13426-tbl-0001){ref-type="table-wrap"} and S2); GADA and IA‐2 autoantibody (IA‐2A) were more common than ZnT8A, but their prevalence did not significantly differ among NGT and HG groups (GADA p = 0.1391, IA‐2A p = 0.7044, ZnT8A p = 0.4818). Kaplan--Meier estimates of HG‐free survival did not significantly differ by pretransplant autoantibody status (Figure S1), even considering number of autoantibodies (Figure S2).

Posttransplant autoantibody positivity, autoantibody number, and conversion are risk factors for HG‐T1DR {#ajt13426-sec-0014}
--------------------------------------------------------------------------------------------------------

Table S2 reports the pre‐ and posttransplant prevalence of each autoantibody according to group. Figure [3](#ajt13426-fig-0003){ref-type="fig"}A shows higher prevalence posttransplant for all autoantibodies only in the HG‐T1DR group. To appropriately examine this dramatic difference, we conducted a paired analysis of the proportion of patients who converted from negative pretransplant to positive on follow‐up, which again was increased only in the HG‐T1DR group (GADA, p = 1.884 × 10^−9^; IA‐2A, p = 9.391 × 10^−8^; ZnT8A, p = 1.682 × 10^−6^) (Figure [3](#ajt13426-fig-0003){ref-type="fig"}B). On follow‐up, autoantibody positivity was specifically associated with increased risk of HG‐T1DR (HR = 14.53, p = 0.0005) (Figure [4](#ajt13426-fig-0004){ref-type="fig"}A) but not with the risk of HG‐PCR and HG‐UND (Figure S3). Multiple autoantibodies were associated with increased risk of HG‐T1DR (Figure [4](#ajt13426-fig-0004){ref-type="fig"}B) but not with HG‐PCR and HG‐UND (Figure S4). Table S3 describes specificity and sensitivity according to number of autoantibodies. Figure [5](#ajt13426-fig-0005){ref-type="fig"} shows the prevalence of autoantibody conversion, persistence, and negativity for each group. The prevalence of conversion was higher in the HG‐T1DR group (p \< 0.0001 vs. negative and persistence); conversion was not associated with HG‐UND and HG‐PCR. Survival analysis confirmed that autoantibody conversion confers increased risk of HG‐T1DR (Figure [4](#ajt13426-fig-0004){ref-type="fig"}C; HR = 27.11, p\<0.0001, conversion vs. negativity; HR = 15.57, p\<0.0003, conversion vs. persistence). There was no effect of autoantibody conversion on HG‐UND or HG‐PCR (Figure S5). Compared to negativity, persistence did not influence risk of hyperglycemia in any of the HG groups (Figure [4](#ajt13426-fig-0004){ref-type="fig"}C and Figure S5). Of 57 patients with autoantibody persistence, all had GADA or IA‐2A persistence, and none had persistent ZnT8A. None of 9 patients with ZnT8A pretransplant had persisting levels as all became negative on follow‐up. Two such patients reacquired ZnT8A on follow‐up as a single autoantibody and were still NGT after 10 years of follow‐up. A third patient converted back to ZnT8A positivity, as well as to positivity for GADA and IA‐2A, and developed HG‐UND 1.9 years after transplantation. Thus, all patients with ZnT8A positivity posttransplant had autoantibody conversions. The specific association of autoantibody positivity and conversion with risk of T1D recurrence was also observed in similar analysis for each of the autoantibodies (data not shown).

![**Pre‐ and posttransplant autoantibody prevalence and conversion.** (A) Pre‐ and posttransplant prevalence of GADA, IA‐2A, and ZnT8A in 223 SPK patients according to group. (B) Prevalence of conversion from autoantibody negative to positive for GADA, IA‐2A, and ZnT8A in 223 SPK patients according to group. P values were calculated using paired Fisher\'s exact test. For both panels, ZnT8A data are shown for 215 patients since pretransplant ZnT8A could not be assessed in eight patients. GADA, 65‐kDa glutamic acid decarboxylase isoform autoantibody; HG‐PCR, hyperglycemia with pancreas chronic rejection; HG‐T1DR, hyperglycemia with type 1 diabetes recurrence; HG‐UND, hyperglycemia of undetermined cause; ZnT8A, ZnT8 autoantibody.](AJT-16-235-g003){#ajt13426-fig-0003}

![**Kaplan--Meier analysis of HG‐T1DR‐free survival according to autoantibodies on follow‐up.** (A) Autoantibody positivity: positive versus negative, HR = 14.53, p = 0.0005; (B) number of autoantibodies: overall, p = 0.0001; 1 versus 0, HR = 3.53, p = 0.2672; 2 versus 0, HR = 14.60, p = 0.0005\*; 3 versus 0, HR = 53.88, p \< 0.0001\*; 2 versus 1, HR = 5.65, p = 0.0131\*\***;** 3 versus 1, HR = 17.04, p\<0.0001\*; 3 versus 2, HR = 3.00, p = 0.0261\*\*; p value \*was or \*\*was not significant after correction for multiple comparisons. (C) Autoantibody conversion:overall, p\<0.0001; persistence versus negative, HR = 1.88, p = 0.6486; conversion versus negative, HR = 27.11, p \< 0.0001\*; conversion versus persistence, HR = 15.57, p = 0.0003\*; \*significant p values after correction for multiple comparisons. HG‐T1DR, hyperglycemia with type 1 diabetes recurrence.](AJT-16-235-g004){#ajt13426-fig-0004}

![**Prevalence of autoantibody conversion, persistence, and negativity in the groups studied.** Results of statistical comparisons are shown in the text box. \*There were no patients in the HG‐PCR group with autoantibody persistence. HG‐PCR, hyperglycemia with pancreas chronic rejection; HG‐T1DR, hyperglycemia with type 1 diabetes recurrence; NGT, normal glucose tolerance.](AJT-16-235-g005){#ajt13426-fig-0005}

Autoantibody patterns in 17 patients with T1D recurrence {#ajt13426-sec-0015}
--------------------------------------------------------

The autoantibody patterns of the 17 HG‐T1DR patients are shown in Table S1C. Most HG‐T1DR patients had autoantibody conversions and/or multiple autoantibodies. The average time from transplantation to the first autoantibody conversion was 3.92 ± SD 3.16 years (range 0.49--11.52 years). The mean time from the first autoantibody conversion to HG‐T1DR was 2.69 ± SD 2.06 years (range 0--5.85 years). We compared time from transplant to conversion, from conversion HG‐T1DR, and duration of positivity, for each autoantibody (Figure [6](#ajt13426-fig-0006){ref-type="fig"}); time from transplant to conversion was similar, but time from ZnT8A conversion to HG‐T1DR (mean 0.66 ± SEM 0.34 years) was shorter compared to IA‐2A (mean 3.36 ± SEM 0.59 years, p = 0.0004) and to GADA (mean 2.27 ± SEM 0.75 years, p = 0.053). The duration of ZnT8A positivity (mean 2.03 ± SEM 0.43 years) was shorter compared to IA‐2A (mean 8.54 ± SEM 1.71 years, p=0.0007) and GADA (mean 5.87 ± SEM 1.73 years, p = 0.030).

![**Assessment of time elapsed from transplant to autoantibody conversion, from conversion to diagnosis, and duration of autoantibody positivity in patients with T1D recurrence.** Data shown as mean ± SEM years. P values of statistically significant comparisons are shown. Data for each patient are presented in Table S1C. GADA, 65‐kDa glutamic acid decarboxylase isoform autoantibody; HG‐T1DR, hyperglycemia with type 1 diabetes recurrence; IA‐2A, IA‐2 autoantibody; ZnT8A, ZnT8 autoantibody.](AJT-16-235-g006){#ajt13426-fig-0006}

Analysis of donor--recipient SLC30A8 gene mismatch {#ajt13426-sec-0016}
--------------------------------------------------

ZnT8 is a cation efflux protein involved in the insulin secretory pathway [30](#ajt13426-bib-0030){ref-type="ref"}, [31](#ajt13426-bib-0031){ref-type="ref"} and is encoded by the SLC30A8 gene. SLC30A8 polymorphisms affect the amino acid sequence at residue 325, an essential determinant of antigenicity [32](#ajt13426-bib-0032){ref-type="ref"}. We investigated whether a donor--recipient genetic mismatch at this locus was associated with ZnT8A and T1D recurrence in 19 donor--recipient pairs (Table S4). Among 10 donor--recipient pairs with a mismatched SLC30A8 genotype, 5 had a mismatch introducing a donor allele not present in the recipient. Comparing to matched or partially mismatched donors, or both, we found no significant differences in the prevalence of T1D recurrence and ZnT8A.

Influence of HLA types and donor--recipient HLA sharing on the development of autoantibody conversion and T1DR {#ajt13426-sec-0017}
--------------------------------------------------------------------------------------------------------------

We analyzed the frequency of HLA‐A, ‐B, and ‐DR alleles associated with T1D risk [33](#ajt13426-bib-0033){ref-type="ref"}. HG‐T1DR patients had increased frequency of the high‐risk DR3/DR4 genotype (52.9%) compared to NGT patients (24.4%, p = 0.02, odds ratio \[OR\] = 3.5, Figure [7](#ajt13426-fig-0007){ref-type="fig"}A). By Kaplan--Meier analysis, this genotype was associated with higher risk of autoantibody conversion (HR = 1.8, p = 0.0488) and T1D recurrence (HR = 2.40, p=0.055) (Figure S6A). Seven HG‐T1DR patients and 9 NGT patients had both conversion and HLA‐DR3/DR4 versus 0 HG‐T1DR and 79 NGT patients who were autoantibody negative and did not carry this genotype (p\<0.0001, OR = 125.5). Thus, having both autoantibody conversion and HLA‐DR3/DR4 conferred much higher risk than having neither, than HLA‐DR3/DR4 (OR = 3.5, p = 0.02) or autoantibody conversion alone (OR = 60.6, p \< 0.0001, Figure [5](#ajt13426-fig-0005){ref-type="fig"}). When examining donor--recipient HLA sharing, class II HLA‐DR alleles (any allele, and DR3) were shared at higher frequency in the HG‐T1DR group compared to NGT (any DR, p = 0.002; DR3, p = 0.003, Figure [7](#ajt13426-fig-0007){ref-type="fig"}B). Survival analysis provides further evidence of an effect of HLA sharing on the development of T1D recurrence (sharing any HLA‐DR, p = 0.0075, HR = 4.57, sharing HLA‐DR3, p = 0.0421, HR = 2.4, Figure S6D and F).

![**Influence of HLA on development of type 1 diabetes recurrence.** (A) Frequencies of T1D‐predisposing HLA variants among simultaneous pancreas--kidney recipients, according to group (HLA‐DR3/DR4, normal glucose tolerance \[NGT\] versus hyperglycemia with type 1 diabetes recurrence \[HG‐T1DR\], p = 0.02; RR = 2.16; OR = 3.5; positive predictive value \[PPV\] = 0.53; sensitivity = 0.17; specificity = 0.94). (B) Frequency of donor--recipient sharing for the HLA types shown. Statistical differences were found for sharing of any HLA‐DR (NGT versus HG‐T1DR, p = 0.002; RR = 3.2; OR = 6.14; PPV = 0.57; sensitivity = 0.97; specificity = 0.16) and of HLA‐DR3 (NGT versus HG‐T1DR, p = 0.003; RR = 1.6; OR = 5.1; PPV = 0.85; sensitivity = 0.94; specificity = 0.23). For both panels, significant p values are shown calculated with the Fisher\'s exact test.](AJT-16-235-g007){#ajt13426-fig-0007}

Discussion {#ajt13426-sec-0018}
==========

T1D recurrence in pancreas transplant recipients is considered rare. Sibley et al [34](#ajt13426-bib-0034){ref-type="ref"} examined 100 pancreas grafts from the 1978 to 1986 period. There were no cases of T1D recurrence among fully immunosuppressed recipients of pancreas grafts from deceased donors. Instead, T1D recurrence was observed in nine identical twins or HLA‐identical siblings who received no or minimal immunosuppression for living‐related grafts [13](#ajt13426-bib-0013){ref-type="ref"}, [14](#ajt13426-bib-0014){ref-type="ref"}, [15](#ajt13426-bib-0015){ref-type="ref"}. Later studies contributed evidence that recurrence of islet autoimmunity may occur regardless of HLA matching [18](#ajt13426-bib-0018){ref-type="ref"}, [24](#ajt13426-bib-0024){ref-type="ref"} and despite immunosuppression [11](#ajt13426-bib-0011){ref-type="ref"}, [12](#ajt13426-bib-0012){ref-type="ref"}, [16](#ajt13426-bib-0016){ref-type="ref"}, [17](#ajt13426-bib-0017){ref-type="ref"}, [18](#ajt13426-bib-0018){ref-type="ref"}, [19](#ajt13426-bib-0019){ref-type="ref"}, [20](#ajt13426-bib-0020){ref-type="ref"}, [21](#ajt13426-bib-0021){ref-type="ref"}, [22](#ajt13426-bib-0022){ref-type="ref"}, [23](#ajt13426-bib-0023){ref-type="ref"}, [24](#ajt13426-bib-0024){ref-type="ref"}, [25](#ajt13426-bib-0025){ref-type="ref"}, [26](#ajt13426-bib-0026){ref-type="ref"}, [27](#ajt13426-bib-0027){ref-type="ref"}, [28](#ajt13426-bib-0028){ref-type="ref"}, [29](#ajt13426-bib-0029){ref-type="ref"}, [35](#ajt13426-bib-0035){ref-type="ref"}. We initially reported [11](#ajt13426-bib-0011){ref-type="ref"} three patients in whom T1D recurrence was characterized by [1](#ajt13426-bib-0001){ref-type="ref"} hyperglycemia requiring insulin with impaired insulin secretion; [2](#ajt13426-bib-0002){ref-type="ref"} seroconversion of autoantibodies years prior to recurrence; [3](#ajt13426-bib-0003){ref-type="ref"} circulating autoreactive T cells around the time of diagnosis, often with simultaneous detection in pancreas transplant and associated lymph nodes; [4](#ajt13426-bib-0004){ref-type="ref"} insulitis and/or beta cell loss in the pancreas transplant biopsy, with no or minimal rejection; and [5](#ajt13426-bib-0005){ref-type="ref"} lack of laboratory evidence of rejection (unchanged urine amylase and serum creatinine levels).

Our study represents the largest evaluation of islet autoimmunity and T1D recurrence in SPK recipients. About one third developed posttransplant diabetes. The three categories of posttransplant diabetes had relatively similar frequency. T1D recurrence was shown in 7.6% of the patients, or 36.2% of the HG group; the diagnosis was validated by biopsy demonstrating insulitis and/or beta cell loss in most patients (15/17) (Table S1A), and thus the prevalence of T1D recurrence confirmed by biopsy was 5.8%. T1D recurrence usually developed on average 6.8 years after transplantation (Table [1](#ajt13426-tbl-0001){ref-type="table-wrap"}), with a wide range of 2.2 to 17.2 years, suggesting that the process can be quite chronic. Some patients also had biopsy evidence of rejection, which was most often minimal to moderate, and only five had decreased urine amylase levels, suggesting that recurrent islet autoimmunity and rejection may at times coexist.

We assessed whether T1D recurrence could have been affected by immunosuppression regimens used over time. We could not identify major effects of maintenance therapy. A small group of patients who did not receive induction therapy experienced higher incidence of T1D recurrence compared to those who had induction; regimens were not compared in a randomized trial and patients were enrolled in different time periods, yet the findings suggest that induction may protect from recurrence, possibly by depleting autoreactive T cells present at transplantation, which could include memory autoreactive T cells that can be reactivated on follow‐up [36](#ajt13426-bib-0036){ref-type="ref"}, [37](#ajt13426-bib-0037){ref-type="ref"}. Importantly, most (157/223, 70%) of the patients studied had been treated with our current immunosuppressive protocol [38](#ajt13426-bib-0038){ref-type="ref"}, [39](#ajt13426-bib-0039){ref-type="ref"}, [40](#ajt13426-bib-0040){ref-type="ref"}.T1D recurrence has continued to occur with the current regimen with an overall prevalence of about 4.6% during the 2000--2013 period. Therefore, current immunosuppression may not prevent recurrence in all patients.

We examined whether T1D‐associated autoantibodies are risk factors for T1D recurrence in our SPK cohort. Earlier but smaller studies examined GADA, IA‐2A, islet cell antibodies and/or insulin autoantibodies in pancreas transplant recipients and reported associations with graft failure, albeit in the absence of biopsy data or analysis of autoreactive T cell responses [22](#ajt13426-bib-0022){ref-type="ref"}, [23](#ajt13426-bib-0023){ref-type="ref"}, [24](#ajt13426-bib-0024){ref-type="ref"}, [25](#ajt13426-bib-0025){ref-type="ref"}, [29](#ajt13426-bib-0029){ref-type="ref"}. Similar to these earlier studies, we find that pretransplant autoantibody positivity does not predict future pancreas graft endocrine function [25](#ajt13426-bib-0025){ref-type="ref"}, [29](#ajt13426-bib-0029){ref-type="ref"}. In contrast, posttransplant autoantibody positivity, multiple autoantibodies, and especially autoantibody conversion were strong predictors of T1D recurrence, similar to the associations reported in prospective studies of relatives [5](#ajt13426-bib-0005){ref-type="ref"}, [7](#ajt13426-bib-0007){ref-type="ref"}. These associations were specific for T1D recurrence, and no associations were found with posttransplant diabetes when this had an undetermined cause or was ascribed to chronic pancreas rejection; a report suggested that pretransplant GADA could be relevant to acute rejection [41](#ajt13426-bib-0041){ref-type="ref"}. Persistence of autoantibodies did not confer increased risk. While previous studies have noted associations of autoantibodies with graft failure [25](#ajt13426-bib-0025){ref-type="ref"}, [29](#ajt13426-bib-0029){ref-type="ref"}, our study is the first to link autoantibodies specifically to biopsy‐confirmed T1D recurrence, and in our own ongoing studies these are being linked to autoimmune T cell responses (Table S1A) [11](#ajt13426-bib-0011){ref-type="ref"}, [42](#ajt13426-bib-0042){ref-type="ref"}.

We also evaluated ZnT8A in our SPK recipients. So far, ZnT8A in transplantation have been studied only in a small cohort of 25 recipients of solitary pancreas transplants [28](#ajt13426-bib-0028){ref-type="ref"}, in whom they predicted loss of pancreas graft function. In our study, ZnT8A were only detected with the high‐risk conversion pattern. Similar to prospective studies of relatives and patients [43](#ajt13426-bib-0043){ref-type="ref"}, [44](#ajt13426-bib-0044){ref-type="ref"}, ZnT8A were the last autoantibodies to become positive on follow‐up, positivity was short lived, and their appearance was much closer to the development of diabetes symptoms (0.66 years vs. 2.27 and 3.63 years for GADA and IA‐2A, respectively). Thus, ZnT8A positivity raises the concern that diabetes recurrence may occur in the near future. As the number of autoantibodies was associated with higher risk (Figure [4](#ajt13426-fig-0004){ref-type="fig"}B), ZnT8A should be used with GADA and IA‐2A testing to identify SPK patients at risk of T1D recurrence.

We examined whether genetic factors could be identified that increase the risk of T1D recurrence. While limited by the small number of informative pairs, our study does not support a donor--recipient mismatch at the SLC30A8 locus as a risk factor for T1D recurrence and ZnT8A. In contrast, we found associations with HLA genes. Given the well‐known associations of certain HLA types with T1D [33](#ajt13426-bib-0033){ref-type="ref"}, we analyzed the frequency of HLA‐A, ‐B, and ‐DR alleles in the SPK recipients as well as HLA sharing with their respective donors. The high‐risk HLA‐DR3/DR4 heterozygous genotype was associated with T1D recurrence; HG‐T1DR SPK patients carried this genotype twice as often as NGT recipients. No association was found with either HLA‐DR4 or HLA‐DR3 alleles, suggesting that T1D recurrence is more common in those with the highest HLA risk. Patients with T1D recurrence also shared HLA‐DR alleles twice as frequently with their donors, an association largely sustained by increased sharing of HLA‐DR3. The HLA‐DR3/DR4 genotype in the recipient and HLA‐DR sharing with the donor were also associated with autoantibody conversions. Importantly, having both autoantibody conversion and HLA‐DR3/DR4 was associated with twice as high the risk of T1D recurrence compared to autoantibody conversion alone. Given the limited number of cases available, we did not apply the Bonferroni correction to the multiple HLA comparisons, yet our data suggest that HLA genes may be important risk factors for the recurrence of islet autoimmunity and T1D in SPK recipients.

We conclude that T1D recurrence is not an uncommon cause of posttransplant diabetes. Our studies identify several risk factors for this condition that could be assessed in transplantation clinics. Autoantibody conversion precedes diabetes symptoms by a few years and is a strong risk factor, especially in those with the HLA‐DR3/DR4 high‐risk genotype. Because ZnT8A positivity equates to autoantibody conversion, it confers high risk of recurrence and typically predicts an imminent diagnosis. Thus, ZnT8A can aid in staging progression of T1D recurrence, a process that in many patients proceeds slowly but will eventually lead to loss of graft endocrine function. The field will benefit from larger studies, to expand and replicate these findings, and possibly identify a sufficient number of patients in whom new therapies can be meaningfully evaluated, given that current immunosuppression cannot prevent T1D recurrence in all patients.
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